Verily Health Inc joins Galvani Bioelectronics as Verily Life Sciences exits
Published
Verily Health Inc. has joined the cap table of Stevenage-based Galvani Bioelectronics Limited, acquiring 2,160 B Ordinary shares. Founded in 2016, the company conducts medical research into bioelectronic medicines. It develops implant-based therapies designed to modulate neural signals to specific organs to treat chronic conditions such as rheumatoid arthritis, bladder dysfunction, and hypertension.
The entry of Verily Health Inc. coincides with the departure of Verily Life Sciences LLC, which exited the cap table after previously holding 1,980 B Ordinary shares. This shareholder change was recorded in a confirmation statement filed 10 June 2026, covering the period from 23 July 2025.
Existing shareholders continue to hold their positions in the company. Setfirst Limited remains the largest shareholder listed in this update with 3,025 shares. Verily Ireland Limited also maintains its stake, holding 495 shares. The company continues its research and development operations from its headquarters in Stevenage. These changes to the ownership structure reflect a shift in the specific Verily entities involved in the business while the overall shareholder base remains concentrated among a small group of investors.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| Exited | VERILY LIFE SCIENCES LLC | 1,980 | — | B ORDINARY 1,980 |
| New shareholder | VERILY HEALTH INC. | 2,160 | — | B ORDINARY 2,160 |
Current shareholders (3)
| Shareholder | Total shares | Share classes |
|---|---|---|
| SETFIRST LIMITED | 3,300 | A ORDINARY 3,300 |
| VERILY HEALTH INC. | 2,160 | B ORDINARY 2,160 |
| VERILY IRELAND LIMITED | 540 | B ORDINARY 540 |
Contact the editorial team at [email protected]